The correlation of vitamin D3 with biochemical markers in β-Thalassemia major patients

Main Article Content

Wasen Jameel Alzubaidi
Mustafa Abd-Almajeed Hussein
Rehab Abdulwehab Jaafer
Newal Khalil Ibrahim

Keywords

Vitamin D3, β-thalassemia major, biochemical markers, BMI, hemoglobinopathy.

Abstract

 


Background: Vitamin D3 is essential for pediatric development and normal growth. Aim: This study aims to analyze the hematological characteristics of both β-thalassemia patients and controls; their liver and renal functions; and calcium, phosphorus, and parathyroid hormone levels and their correlation with vitamin D3. Methods: Ninety teenage subjects, comprising 45 patients with β-thalassemia major (selected from the Hereditary Blood Diseases Center in Basrah during their regular checkups) and 45 apparently healthy individuals selected from relatives and friends, aged between 12 to 15 years (42.2% males and 57.8% females) were included in a 2023 case-control study at the Hereditary Blood Diseases Center. A gel tube with approximately 5 mL of blood was utilized for biochemical analyses, and a portion of the sample was transferred into a test tube for complete blood count testing. Liver and renal functions were evaluated by measuring the activities of aspartate transaminase (AST), alkaline phosphatase (ALP), alanine transaminase (ALT), blood urea, and serum creatinine. Serum concentrations of parathyroid hormone, vitamin D3, calcium, and phosphorus were also estimated. Serum ferritin and complete blood count were performed as well. The Statistical Package for the Special Science version 29 was utilized, employing several methods to assess the connection between the variables, including the Mann-Whitney U test, Pearson Chi-Square, Pearson correlation, and linear regression (to assess the correlation between the variables). A p-value of < 0.05 was considered statistically significant. Results: Regarding demographics, the only significant difference was in BMI (p = 0.0001). ALT, AST, and ALP levels were significantly higher in β-thalassemia patients compared to healthy individuals, with significant differences (p = 0.0001 for all). Blood urea and serum creatinine levels were statistically significant (p = 0.0001). A highly significant difference was found in serum levels of vitamin D3 (p = 0.0001), with PTH significantly higher in patients (p = 0.0001). Calcium levels were also significantly different (p = 0.0001), but no significant difference was found in phosphorus levels (p > 0.05). Regarding hematological indices, a highly significant association was found in Hb, RBC, HCT (p = 0.0001), and MCV (p = 0.025) levels, while MCH, MCHC, WBCs, and platelets did not have significant differences (p > 0.05). Conclusion: β-Thalassemia significantly affects hematological and biochemical markers in all patients. Vitamin D3 levels are negatively correlated with ALT, AST, serum ferritin, PTH, and calcium levels in patients.


 


 

Abstract 67 | Full text PDF Downloads 45

References

1. Israa Gabar Hasoon, Wafaa Sadoon Shani, Aliaa Mohammed Radi. The association of hepcidin with some inflammatory markers in β-thalassemia major patients of Basrah Province. Eurasia J Biosci 2020;14, 7285-7289.
2. Jee-Soo Lee SI, et al. Molecular basis and diagnosis of Thalassemia. Blood Research. 2021;56(S1): S39-S43.doi: 10.5045/br.2021.2020332
3. Alsaeed ES, Farhat GN, Assiri AM, et al. Distribution of hemoglobinopathy disorders in Saudi Arabia based on data from the premarital screening and genetic counseling program, 2011–2015. Journal of Epidemiology and Global Health. 2018; S41-S47.doi: 10.1016/j.jegh.2017.12.001
4. Harteveld CL, Achour A, et al. The hemoglobinopathies, molecular disease mechanisms and diagnostics. International Journal of Laboratory Hematology. 2022;44(S1): 28-36.doi: 10.1111/ijlh.13885
5. Tepakhan W, Kanjanaopas S, et al. Molecular epidemiology and hematological profiles of hemoglobin variants in Southern Thailand. Scientific Reports. 2024;14(1). doi:10.1038/s41598-024-59987-4
6. Shafique F, Ali S, Almansouri T, et al. Thalassemia, a human blood disorder. Brazilian Journal of Biology. 2023; 83.doi: 10.1590/1519-6984.246062
7. Akhavan-Niaki H, Derakhshandeh-Peykar P, et al. A comprehensive molecular characterization of Beta Thalassemia in a Highly Heterogeneous Population. Blood Cells, Molecules, and Diseases. 2011;47(1): 29-32.doi: 10.1016/j.bcmd.2011.03.005
8. Yang J, Li Q, Feng Y, Zeng Y. Iron deficiency and iron deficiency anemia: potential risk factors in bone loss. In International Journal of Molecular Sciences. 2023; 24(8). doi:10.3390/ijms24086891
9. Al-Rubae AM, Ansaf AI, Faraj SA. Evaluation of Vitamin D Level in thalassemia patients: the experience of a single center. Iraqi Journal of Hematology. 2023;12(2): 141-145.doi: 10.4103/ijh.ijh_57_23
10. Saggese G, Vierucci F, Prodamet F, et al. Vitamin d in pediatric age: consensus of the Italian Pediatric Society and the Italian Society of Preventive and Social Pediatrics, jointly with the Italian Federation of Pediatricians. Italian Journal of Pediatrics. 2018;44:51.doi:10.1186/s13052-018-0488-7
11. Rivella S. Iron metabolism under conditions of ineffective erythropoiesis in β-Thalassemia. Blood. 2019;133(1): 51-58.doi: 10.1182/blood-2018-07-815928.
12. Milad Azami A, Sharifi A, Norozi S, et al. Prevalence of diabetes, impaired fasting glucose and impaired glucose tolerance in patients with thalassemia major in Iran: a meta-analysis study. Caspian Journal of Internal Medicine. 2017;8(1): 1-15. PMID: 28503277
13. Gharehdaghi, Z, Rostami Yasuj, S. Hematological and biochemical parameters of β-thalassemia major patients in Bushehr city: a comparative analysis. International Journal of Medical Laboratory. 2023. doi:10.18502/ijml.v10i1.12426
14. Sultan, S, Irfan, SM, Ahmed, SI. Biochemical markers of bone turnover in patients with β-thalassemia major: a single center study from Southern Pakistan. Advances in Hematology. 2016. doi:10.1155/2016/5437609
15. Ali Akbar Asadi-Pooya, HK Body mass index in children with beta-thalassemia major. Turkish Journal of Hematology. 2004; 21(4):177-180.
16. Vogiatzi MG, Macklin, EA, Trachtenberg FL, et al., Giardina. Differences in the prevalence of growth, endocrine and vitamin d abnormalities among the various thalassemia syndromes in North America. British Journal of Hematology. 2009;146(5): 546-556.doi:10.1111/j.1365-2141.2009. 07793.x
17. Soliman A, Yassin M, Alyafei F et al. Nutritional studies in patients with β-thalassemia major: a short review, Acta Biomedica. 2023; 94(3): e2023187.doi: 10.23750/abm.v94i3.1473210.23750/abm. v94i3.14732
18. Karim, MF, Ismail M, Hasan, AM, Shekhar HU. Hematological and biochemical status of beta-thalassemia major patients in Bangladesh: A comparative analysis. International Journal of Hematology and Oncology Stem Cell Research. 2016;10(1):7-12.PMID: 27047645
19. Khawaji M, Hazzazi A, Ageeli M et al. Clinical and hematological features among β-thalassemia major patients in Jazan Region: a hospital-based study. J Family Med Prim Care. 2020 Jan;9(1): 412-417. doi: 10.4103/jfmpc.jfmpc_1007_19
20. Zahim Hussein, S. Evaluation of thyroid hormones and ferritin level in patients with β-thalassemia. Medicine and Pharmacy Reports. 2022 Apr;95(2):152-157. doi: 10.15386/mpr-2053
21. Salama KM, Ibrahim OM, Kaddah AM, Boseila S, Ismail LA, Abdel Hamid MM. Liver enzymes in children with beta-thalassemia major: correlation with iron overload and viral hepatitis. Open Access Macedonian Journal of Medical Sciences. 2015;3(2):287-292. doi:10.3889/oamjms.2015.059
22. Mahmoud, Asmaa A, Elian, Doaa M. et al. Assessment of subclinical renal glomerular and tubular dysfunction in children with beta-thalassemia major. Children. 2021;8(2): 100. doi: 10.3390/children8020100
23. Şen V, Ece A, Uluca U, Söker M, et al. Renal Failure. 2015 May;37(4):607-13. doi: 10.3109/0886022X.2015.1007871.
24. Dimitriadou M, Christoforidis A, Economou M et al. Elevated serum parathormone levels are associated with myocardial iron overload in patients with β-thalassaemia major. European Journal of Hematology. 2009. doi:10.1111/j.1600-0609.2009.01349.x
25. Ashraf Soliman VDS, MY. Vitamin d status in thalassemia major: an update. Mediterranean Journal of Hematology and Infectious Disease. 2013;5(1): e2013057. doi:10.4084/MJHID.2013.057
26. Shamshirsaz AA, Bekheirnia MR, Kamgar M, Pourzahedgilani N, Bouzari N, Habibzadeh M, Hashemi R, Shamshirsaz AHA, Aghakhani S, Homayoun H, Larijani B. Metabolic and endocrinologic complications in beta-thalassemia major: a multicenter study in Tehran. BMC Endocrine Disorders. 2003;3. doi:10.1186/1472-6823-3-4
27. Marco Di Stefano P, Chiabotto P, Roggia C, et al. Bone mass and metabolism in thalassemic children and adolescents treated with different iron-chelating drugs. Journal of Bone and Mineral Metabolism. 2004;22(1), 53-57. doi:10.1007/s00774-003-0449-z
28. Pirinççioğlu AG, Akpolat A, Köksal O, et al. Bone mineral density in children with beta-thalassemia major in Diyarbakir. Bone. 2011;49(4): 819-823. doi: 10.1016/j.bone.2011.07.014.
29. Abdelmotaleb, GS, Behairy, OG, El Azim, KEA, et al. Assessment of serum vitamin d levels in Egyptian children with beta-thalassemia major. Egyptian Pediatric Association Gazette. 2021;69(1). doi: 10.1186/s43054-021-00066-y

Similar Articles

1-10 of 36

You may also start an advanced similarity search for this article.